Interleukin-22/Interleukin-22 binding protein axis and oral contraceptive use in polycystic ovary syndrome - PubMed (original) (raw)

Interleukin-22/Interleukin-22 binding protein axis and oral contraceptive use in polycystic ovary syndrome

Seren Aksun et al. Endocrine. 2023 Jul.

Abstract

Purpose: Polycystic ovary syndrome (PCOS) is associated with alterations in gut microbiota. The cytokine interleukin-22 (IL-22) is produced by immune cells and closely linked to gut immunity, which is tightly controlled by its binding protein (IL-22BP). In this study, we aimed to assess whether IL-22/IL-22BP axis is altered in PCOS at baseline and in response to short-term oral contraceptive (OC) therapy.

Methods: We have evaluated circulating concentrations of IL-22 and IL-22BP in serum samples of 63 PCOS patients and 39 age- and BMI-matched healthy controls. Blood samples were taken in the early follicular phase of a cycle and stored at -80 °C. Serum IL-22 and IL-22BP levels were measured by ELISA at baseline in both women with PCOS and controls, and after 3 months of OC use in PCOS group. IL-22/IL-22BP ratio was calculated in order to have a better reflection of IL-22 biological activity.

Results: At baseline, serum IL-22, IL-22BP concentrations and IL22/IL-22BP ratio were similar between women with PCOS and healthy controls. Three months of OC use along with general lifestyle advice resulted in a significant increase in IL-22/IL-22BP ratio in the PCOS group (62.4 [IQR:14.7-172.7] at baseline vs 73.8 [IQR:15.1-264.3] after OC use respectively p = 0.011).

Conclusions: Results of this study show that women with PCOS have similar circulating concentrations of IL-22 and IL-22BP with healthy women and that short term oral contraception is associated with an increase in IL-22/IL-22BP ratio suggesting higher biological activity of the IL-22 system with OC use in PCOS.

Keywords: IL-22; IL-22 binding protein; Microbiota; Oral contraceptive; Polycystic ovary syndrome.

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PubMed Disclaimer

References

    1. B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, H. Yarali, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27(10), 3067–3073 (2012). https://doi.org/10.1093/humrep/des232 - DOI - PubMed
    1. R.C.E. Azziz, Z. Chen, A. Dunaif, J.S. Laven, R.S. Legro, D. Lizneva, B. Natterson-Horowtiz, H.J. Teede, B.O. Yildiz, Polycystic ovary syndrome. (2016). https://doi.org/10.1038/nrdp.2016.57
    1. G. Mammadova, C. Ozkul, S. Yilmaz Isikhan, A. Acikgoz, B.O. Yildiz, Characterization of gut microbiota in polycystic ovary syndrome: Findings from a lean population. Eur. J. Clin. Investig. 51(4), e13417 (2021). https://doi.org/10.1111/eci.13417 - DOI
    1. X. Qi, C. Yun, L. Sun, J. Xia, Q. Wu, Y. Wang et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat. Med. 25(8), 1225–1233 (2019). https://doi.org/10.1038/s41591-019-0509-0 - DOI - PubMed - PMC
    1. G. Conway, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, S. Franks, A. Gambineri et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 171(4), P1–P29 (2014). https://doi.org/10.1530/eje-14-0253 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources